Filgotinib Demonstrates Favorable Safety in Pooled Analysis of Phase III Studies in Patients With Rheumatoid Arthritis

November 8-13, 2019; Atlanta, Georgia
Results of this pooled analysis of 3 randomized, controlled phase III trials show filgotinib to be well tolerated, with no new safety signals, and low rates of MACE/VTE.
Format: Microsoft PowerPoint (.ppt)
File Size: 192 KB
Released: November 18, 2019

Acknowledgements

Provided by the Annenberg Center for Health Sciences at Eisenhower
ACHS Logo

Annenberg Center for Health Sciences at Eisenhower
39000 Bob Hope Dr
Dinah Shore Bldg.
Rancho Mirage, CA 92270

Melissa Velasquez, Accreditation Specialist
(760) 773-4506
(760) 773-4550 (Fax)
ce@annenberg.net
http://www.annenberg.net/

Supported by educational grants from
Gilead Sciences
Mallinckrodt Pharmaceuticals

Related Content

Interstitial lung disease (ILD) is a frequent complication of the autoimmune disorder systemic sclerosis (SSc). SSc-ILD remains a challenging condition to identify, treat, and manage. Early identification of ILD in patients with SSc is critical so that treatment can be initiated as soon as possible. However, utilization of optimal screening and diagnosis strategies is low among healthcare providers. Treatment decisions also represent a significant clinical challenge; a lack of guidance and effective treatments results in suboptimal practice and gaps in knowledge among providers. While new agents are on the horizon, dissemination of clinical trial data and uptake of new agents may be delayed. Monitoring of SSc-ILD patients is equally difficult, and research suggests suboptimal practice related to this aspect of care. Finally, poor patient-provider communication amplifies these challenges and contributes to patient anxiety.

Flavia Castelino, MD
Program Director
Jane E. Dematte, MD, MBA Mary Beth Scholand, MD
Physicians: maximum of 1.0 AMA PRA Category 1 Credit Released: September 30, 2019 Expired: September 30, 2020

Audio: New Crohn’s and ulcerative colitis clinical data from ACG and DDW 2018. From Francis A. Farraye, MD, MSc.

Francis Farraye Headshot Francis A. Farraye, MD, MSc Released: November 7, 2018

Full IBD slides: New Crohn’s and ulcerative colitis clinical data from ACG and DDW 2018. From Francis A. Farraye, MD, MSc.

Francis Farraye Headshot Francis A. Farraye, MD, MSc Released: October 25, 2018

Emerging Crohn’s and ulcerative colitis treatments and targets: integrins, JAK inhibitors, IL-12/23 inhibitors, S1P1 modulators, fecal transplant (FMT)

Gary Lichtenstein Headshot Gary R. Lichtenstein, MD Released: October 3, 2018

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?